Hopp til hovedinnhold

Covid-19-vaksiner

Sist oppdatert: Sist revidert:
Sist revidert av:


  1. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. MMWR 2020; 69: 1922-4. doi:10.15585/mmwr.mm6950e2 DOI  
  2. Folkehelseinstituttet. Vaksinasjonsveilderen. Koronavaksine. Sist oppdatert 06.09.2021. Siden lest 13.09.2021. www.fhi.no  
  3. Fell DB, Dhinsa T, Alton GD, et al. Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. JAMA 2022. pmid:35323842 PubMed  
  4. Fell DB, Dimanlig-Cruz S, Regan AK, et al. Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study. BMJ 2022; 378: e071416. doi:10.1136/bmj-2022-071416 DOI  
  5. FDA. Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine. FDA News Release 25.02.2021. www.fda.gov  
  6. MMWR. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021. www.cdc.gov  
  7. Statens legemiddelverk. Nyheter. Meldte bivirkninger etter koronavaksine pr. 14. januar 2021 og Bruk av mRNA-vaksiner hos eldre. Publisert 14.01.2021. Siden besøkt 18.01.2021 legemiddelverket.no  
  8. Jabagi MJ, Botton J, Bertrand M, et al. Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA 2021. pmid:34807248 PubMed  
  9. Felleskatalogen. Comirnaty. Sist oppdatert 29.12.2020. Siden lest 07.01.2020. www.felleskatalogen.no  
  10. CDC COVID-19 Response Team and Food and Drug Administration Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep 2021 Jan 15; 70:46. doi: 10.15585/mmwr.mm7002e1 DOI  
  11. Blumenthal KG, Robinson LB, Camargo CA, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA 2021. doi:10.1001/jama.2021.3976 DOI  
  12. Alnæs M, Storaas T, Sørensen M, et al. Covid-19-vaksiner gir økt risiko for anafylaksi. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.21.0109 DOI  
  13. Renoud L, Khouri C, Revol B, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med 2021. doi:10.1001/jamainternmed.2021.2219 DOI  
  14. Li X, Raventos B, Roel E, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ 2022; 376: e068373. pmid:35296468 PubMed  
  15. Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiology 2021. pmid:34185045 PubMed  
  16. Pillay J, Gaudete L, Wingert A, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ 2022; 378: e069445. doi:10.1136/bmj-2021-069445 DOI  
  17. Statens legemiddelverk. Myokarditt etter koronavaksinasjon. Nytt om legemidler nr. 16, 2021. nhi.no  
  18. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol 2022. pmid:35442390 PubMed  
  19. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep 2021 Mar 29. https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm.
  20. Haas EJ, Angulo FJ, McLaughlin JM, et al . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021. doi:10.1016/ S0140-6736(21)00947-8
  21. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. . Lancet 2021. pmid:34619098 PubMed  
  22. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021. pmid:34756184 PubMed  
  23. CDC COVID-19 Response Team and Food and Drug Administration Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep 2021. doi: 10.15585/mmwr.mm7004e1 DOI  
  24. Blumenthal KG, Freeman EF, Saff RR, et al. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med 2021. doi:10.1056/NEJMc2102131 DOI  
  25. Diaz GA, Parsons GT, Gering SK, et al. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA 2021. pmid:34347001 PubMed  
  26. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020. PMID: 33378609 PubMed  
  27. Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv 2021. doi:10.1101/2021.03.01.21252652 DOI  
  28. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021. doi:10.1056/NEJMoa2102214 DOI  
  29. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021. pmid:33835768 PubMed  
  30. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 2021; 373: n1114. pmid:33952445 PubMed  
  31. European Medicines Agency (EMA). Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. EMA News 11.06.2021 www.ema.europa.eu  
  32. Statens Legemiddelverk. Tredje koronarvaksine godkjent i Europa. Nyheter 29.02.2021 legemiddelverket.no  
  33. WHO. WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out. WHO News 15.02.2021. www.who.int  
  34. Voysey M, Clemens SUA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021. pmid:33617777 PubMed  
  35. Statens legemiddelverk. Fakta om godkjente koronavaksiner. Covid-19 Vaccine Janssen. legemiddelverket.no  
  36. Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA 2021. doi:10.1001/jama.2021.3645 DOI  
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL